Advanced

Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study

Sonestedt, Emily LU ; Borgquist, Signe LU ; Ericson, Ulrika LU ; Gullberg, Bo LU ; Olsson, Håkan LU ; Adlercreutz, Herman; Landberg, Göran LU and Wirfält, Elisabet LU (2008) In Cancer Epidemiology Biomarkers & Prevention 17(11). p.51-3241
Abstract

BACKGROUND: Differences in the estrogen receptor (ER) status of tumors may explain ambiguities in epidemiologic studies between the blood concentrations of enterolactone and breast cancer. To our knowledge, the association between enterolactone and ERbeta-defined breast cancer has previously not been examined.

METHODS: A nested case-control study within the Malmö Diet and Cancer cohort used 366 cases and 733 matched controls to identify the major determinants of plasma enterolactone and to examine the association between enterolactone concentration and breast cancer risk and if this association differs depending on the ERalpha and ERbeta status of tumors. A modified diet history method assessed dietary habits. Time-resolved... (More)

BACKGROUND: Differences in the estrogen receptor (ER) status of tumors may explain ambiguities in epidemiologic studies between the blood concentrations of enterolactone and breast cancer. To our knowledge, the association between enterolactone and ERbeta-defined breast cancer has previously not been examined.

METHODS: A nested case-control study within the Malmö Diet and Cancer cohort used 366 cases and 733 matched controls to identify the major determinants of plasma enterolactone and to examine the association between enterolactone concentration and breast cancer risk and if this association differs depending on the ERalpha and ERbeta status of tumors. A modified diet history method assessed dietary habits. Time-resolved fluoroimmunoassay determined enterolactone concentrations and immunohistochemistry using tissue microarray determined ER status.

RESULTS: Dietary fiber, as well as fruits and berries, and high-fiber bread showed statistically significant correlations with enterolactone (r, 0.13-0.22). Smoking and obesity were associated with lower enterolactone concentrations. Enterolactone concentrations above the median (16 nmol/L) were associated with reduced breast cancer risk when compared with those below [odds ratio, 0.75; 95% confidence interval (95% CI), 0.58-0.98]. The reduced risk was only observed for ERalpha [positive (+); odds ratio, 0.73; 95% CI, 0.55-0.97] and ERbeta [negative (-)] tumors (odds ratio, 0.60; 95% CI, 0.42-0.84), with significantly different risks for ERbeta (-) and ERbeta (+) tumors (P for heterogeneity = 0.04).

CONCLUSIONS: This study supports the suggestion that enterolactone is a biomarker of a healthy lifestyle. The protective association between enterolactone and breast cancer was significantly different between ERbeta (-) and ERbeta (+) tumors and most evident in tumors that express ERalpha but not ERbeta.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
4-Butyrolactone, Adult, Aged, Biomarkers, Tumor, Breast Neoplasms, Case-Control Studies, Diet, Estrogen Receptor alpha, Estrogen Receptor beta, Female, Humans, Lignans, Linear Models, Microarray Analysis, Middle Aged, Obesity, Prospective Studies, Reproducibility of Results, Risk Assessment, Smoking, Surveys and Questionnaires, Sweden
in
Cancer Epidemiology Biomarkers & Prevention
volume
17
issue
11
pages
11 pages
publisher
American Association for Cancer Research
external identifiers
  • wos:000260896500045
  • pmid:18990767
  • scopus:55849089067
ISSN
1538-7755
DOI
10.1158/1055-9965.EPI-08-0393http://dx.doi.org/10.1158/1055-9965.EPI-08-0393
language
English
LU publication?
yes
id
a5c75956-a69a-4dfd-bcb3-4dd78e5ff66e (old id 1271714)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18990767?dopt=Abstract
date added to LUP
2008-12-01 16:45:06
date last changed
2017-01-01 06:14:45
@article{a5c75956-a69a-4dfd-bcb3-4dd78e5ff66e,
  abstract     = {<p>BACKGROUND: Differences in the estrogen receptor (ER) status of tumors may explain ambiguities in epidemiologic studies between the blood concentrations of enterolactone and breast cancer. To our knowledge, the association between enterolactone and ERbeta-defined breast cancer has previously not been examined.</p><p>METHODS: A nested case-control study within the Malmö Diet and Cancer cohort used 366 cases and 733 matched controls to identify the major determinants of plasma enterolactone and to examine the association between enterolactone concentration and breast cancer risk and if this association differs depending on the ERalpha and ERbeta status of tumors. A modified diet history method assessed dietary habits. Time-resolved fluoroimmunoassay determined enterolactone concentrations and immunohistochemistry using tissue microarray determined ER status.</p><p>RESULTS: Dietary fiber, as well as fruits and berries, and high-fiber bread showed statistically significant correlations with enterolactone (r, 0.13-0.22). Smoking and obesity were associated with lower enterolactone concentrations. Enterolactone concentrations above the median (16 nmol/L) were associated with reduced breast cancer risk when compared with those below [odds ratio, 0.75; 95% confidence interval (95% CI), 0.58-0.98]. The reduced risk was only observed for ERalpha [positive (+); odds ratio, 0.73; 95% CI, 0.55-0.97] and ERbeta [negative (-)] tumors (odds ratio, 0.60; 95% CI, 0.42-0.84), with significantly different risks for ERbeta (-) and ERbeta (+) tumors (P for heterogeneity = 0.04).</p><p>CONCLUSIONS: This study supports the suggestion that enterolactone is a biomarker of a healthy lifestyle. The protective association between enterolactone and breast cancer was significantly different between ERbeta (-) and ERbeta (+) tumors and most evident in tumors that express ERalpha but not ERbeta.</p>},
  author       = {Sonestedt, Emily and Borgquist, Signe and Ericson, Ulrika and Gullberg, Bo and Olsson, Håkan and Adlercreutz, Herman and Landberg, Göran and Wirfält, Elisabet},
  issn         = {1538-7755},
  keyword      = {4-Butyrolactone,Adult,Aged,Biomarkers, Tumor,Breast Neoplasms,Case-Control Studies,Diet,Estrogen Receptor alpha,Estrogen Receptor beta,Female,Humans,Lignans,Linear Models,Microarray Analysis,Middle Aged,Obesity,Prospective Studies,Reproducibility of Results,Risk Assessment,Smoking,Surveys and Questionnaires,Sweden},
  language     = {eng},
  number       = {11},
  pages        = {51--3241},
  publisher    = {American Association for Cancer Research},
  series       = {Cancer Epidemiology Biomarkers & Prevention},
  title        = {Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study},
  url          = {http://dx.doi.org/10.1158/1055-9965.EPI-08-0393http://dx.doi.org/10.1158/1055-9965.EPI-08-0393},
  volume       = {17},
  year         = {2008},
}